These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22566376)

  • 1. Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment.
    Nüesch JP; Lacroix J; Marchini A; Rommelaere J
    Clin Cancer Res; 2012 Jul; 18(13):3516-23. PubMed ID: 22566376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic parvoviruses as cancer therapeutics.
    Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
    Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
    Hartley A; Kavishwar G; Salvato I; Marchini A
    Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic parvoviruses: from basic virology to clinical applications.
    Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
    Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
    Shmulevitz M; Lee PW
    Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-faceted mechanism of parvoviral oncosuppression.
    Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
    Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
    Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
    Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells.
    Abschuetz A; Kehl T; Geibig R; Leuchs B; Rommelaere J; Régnier-Vigouroux A
    Cell Tissue Res; 2006 Sep; 325(3):423-36. PubMed ID: 16699801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures.
    Muharram G; Le Rhun E; Loison I; Wizla P; Richard A; Martin N; Roussel A; Begue A; Devos P; Baranzelli MC; Bonneterre J; Caillet-Fauquet P; Stehelin D
    Breast Cancer Res Treat; 2010 May; 121(1):23-33. PubMed ID: 19565332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oncolytic viruses: riding high on the next wave?
    Stanford MM; Bell JC; Vähä-Koskela MJ
    Cytokine Growth Factor Rev; 2010; 21(2-3):177-83. PubMed ID: 20219409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virotherapy for cancer treatment: challenges and solutions.
    Davis JJ; Fang B
    J Gene Med; 2005 Nov; 7(11):1380-9. PubMed ID: 16025557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.
    Angelova A; Rommelaere J
    Viruses; 2019 May; 11(5):. PubMed ID: 31060205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review.
    Geletneky K; Herrero Y Calle M; Rommelaere J; Schlehofer JR
    J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):327-30. PubMed ID: 16316394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer.
    Shmulevitz M; Marcato P; Lee PW
    Oncogene; 2005 Nov; 24(52):7720-8. PubMed ID: 16299532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control.
    Mohr I
    Oncogene; 2005 Nov; 24(52):7697-709. PubMed ID: 16299530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.
    Thorne SH; Hermiston T; Kirn D
    Semin Oncol; 2005 Dec; 32(6):537-48. PubMed ID: 16338419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.